GlaxoSmithKline

GSK
Real-time CHI-X EUROPE LIMITED. - 02/25 03:47:02 am
1629.8GBp
+0.10%
Income Statement Evolution
Annual Income Statement Data
Actuals in M GBP Estimates in M GBP
Fiscal Period December 2019 2020 (e)
Sales 33 754 34 843
EBITDA 11 968 11 170
Operating profit (EBIT) 8 972 9 123
Pre-Tax Profit (EBT) 6 221 7 019
Net income 4 645 4 300
P/E ratio 19,2x 19,2x
EPS ( GBp ) 92,6 84,7
Dividend per Share ( GBp ) 80,0 80,0
Yield 4,50% 4,91%
Reference price ( GBp ) 1 779,000 1 629,800
Announcement Date 02/05/2020
12:00pm
-
Finances - Leverage
Actuals in M GBP Estimates in M GBP
Fiscal Period December 2019 2020 (e)
Debt 25 722 23 712
Finance - -
Operating income (EBITDA) 11 968 11 170
Leverage
(Debt/EBITDA)
2,15x 2,12x
Capital Expenditure 1 265 1 522
Free Cash Flow (FCF) 5 073 5 344
Book Value Per Share (BVPS) ( GBp ) 242 238
Cash Flow per Share ( GBp ) 160 136
Announcement Date 02/05/2020
12:00pm
-
Balance Sheet Analysis
Financial Ratios
Size 2020e 2021e
Capitalization 81 108 M GBP -
Entreprise Value (EV) 104 820 M GBP 102 681 M GBP
Valuation 2020e 2021e
P/E ratio (Price / EPS) 19,2x 18,6x
Capitalization / Revenue 2,33x 2,26x
EV / Revenue 3,01x 2,92x
EV / EBITDA 9,38x 9,03x
Yield (DPS / Price) 4,91% 4,91%
Price to book (Price / BVPS) 6,84x 7,37x
Profitability 2020e 2021e
Operating Margin (EBIT / Sales) 26,2% 26,5%
Operating Leverage (Delta EBIT / Delta Sales) 0,52x 1,38x
Net Margin (Net Profit / Revenue) 12,3% 12,8%
ROA (Net Profit / Asset) 5,93% 6,22%
ROE (Net Profit / Equities) 43,9% 55,4%
Rate of Dividend 94,4% 91,5%
Balance Sheet Analysis 2020e 2021e
CAPEX / Sales   4,37% 4,34%
Cash Flow / Sales 19,5% 20,2%
Capital Intensity (Assets / Sales) 2,08x 2,06x
Financial Leverage (Net Debt / EBITDA) 2,12x 1,86x
Price Earning Ratio
BNA & Dividende